SPEND AND COMPLIANCE DATA RESPONSIBILITIES Sample Clauses

SPEND AND COMPLIANCE DATA RESPONSIBILITIES involve significant interactions between the Parties. The Interaction Models the Parties have developed, as of the Effective Date, are set forth in Annex A-8 (Interaction Models). By mutual written agreement of the Parties’ Project Executives, the Parties may modify the attached Interaction Models or develop additional Interaction Models without requiring amendment of the Agreement. Spend and compliance data are available from three sources, the P2P Platform, Solectron’s ERP and financial systems and the suppliers. IBM is responsible for gathering spend and compliance data from the P2P and to the extent it is required and it is reasonably commercially available, from the supplier. If such data are required from Solectron’s ERP and financial systems to the extent that it is reasonably commercially available, Solectron is responsible for gathering such data, and providing the same to IBM in the format reasonably required by IBM. For the purposes of performing the Services Groupings with respect to the Elements for which IBM (or Solectron) is identified as the Actor in Annex A-1 IBM (or Solectron) is responsible for analyzing such data to the extent those responsibilities are identified in Annex A-1. For the purposes of determining Actual Savings, Compliance Rates and adjustments to the Committed Strategic and Tactical Sourcing Savings as discussed in Schedule B (Performance Management) and Annexe B-1 (Savings Calculation Methodology), IBM is responsible for the analysis of all spend and compliance data irrespective of the source. Confidential to Solectron and IBM Annex A-1 STATEMENT OF WORK/ SCOPE MODELS [Attached] Confidential to Solectron and IBM Annex A-2 PROCESSES DEFINITIONS [Attached] Confidential to Solectron and IBM Annex A-3 [Reserved] Confidential to Solectron and IBM Annex A-4 [Reserved] Confidential to Solectron and IBM Annex A-8 INTERACTION MODEL(S) [Attached] Confidential to Solectron and IBM * Omitted and filed separately with the SEC pursuant to a confidential treatment request Annex A-1 Matrix A1 — 1 PROCESS — SERVICE GROUPING [*] Confidential to Solectron and IBM Annex A-1 Matrix A1 - 2-a SERVICE GROUPING — ELEMENT PASS THROUGH * Omitted and filed separately with the SEC pursuant to a confidential treatment request [*] Confidential to Solectron and IBM Annex A-1 Matrix A1 - 2-b SERVICE GROUPING — ELEMENT P2P * Omitted and filed separately with the SEC pursuant to a confidential treatment request [*] Confidential to Solectron and IBM Annex A...
Sample 1
AutoNDA by SimpleDocs

Related to SPEND AND COMPLIANCE DATA RESPONSIBILITIES

  • Specific Responsibilities In addition to its overall responsibility for monitoring and providing a forum to discuss and coordinate the Parties’ activities under this Agreement, the JSC shall in particular:

  • Contractor Responsibilities It shall be Tenant’s responsibility to cause each of Tenant’s contractors and subcontractors to:

  • Customer Responsibilities (a) The Customer agrees to (i) promptly notify the Bank of any change that the Customer wishes to make to Exhibit B, (ii) promptly notify the Bank if any information contained in the Customer Information Sheet becomes inaccurate or untrue and (iii) indemnify the Bank for any losses resulting from the Customer's failure to adhere to the provisions of Subsection (a) of this Section 11.

  • Client Responsibilities During the Term and subject to the provisions of this Schedule, Client shall at its expense (unless otherwise provided for herein) fulfill, or cause to be fulfilled by the Funds or otherwise, the Client obligations, if any, set forth in each Service Exhibit to this Schedule. Client hereby represents, warrants and covenants that the execution and delivery of this Schedule by Client and the performance of Client’s obligations under this Schedule have been duly authorized by all necessary action on the part of Client. Client must comply with the provisions of this Schedule. Client agrees that DST may seek relief from Client for any infringement of this Schedule such as, but not limited to, a material violation, breach, act of negligence or gross negligence, willful misconduct, misfeasance or malfeasance committed by Client or its officers, agents and assigns, in connection with Client’s obligations and responsibilities under this Schedule.

  • Monitoring Responsibilities The Custodian shall furnish annually to the Fund, during the month of June, information concerning the foreign sub-custodians employed by the Custodian. Such information shall be similar in kind and scope to that furnished to the Fund in connection with the initial approval of this Contract. In addition, the Custodian will promptly inform the Fund in the event that the Custodian learns of a material adverse change in the financial condition of a foreign sub-custodian or any material loss of the assets of the Fund or in the case of any foreign sub-custodian not the subject of an exemptive order from the Securities and Exchange Commission is notified by such foreign sub-custodian that there appears to be a substantial likelihood that its shareholders' equity will decline below $200 million (U.S. dollars or the equivalent thereof) or that its shareholders' equity has declined below $200 million (in each case computed in accordance with generally accepted U.S. accounting principles).

  • Company Responsibilities The Company will undertake responsibilities as set forth below:

  • ALPS’ Responsibilities In connection with its performance of TA Web, ALPS shall:

  • Compliance Control Services (1) Support reporting to regulatory bodies and support financial statement preparation by making the Fund's accounting records available to the Trust, the Securities and Exchange Commission (the “SEC”), and the independent accountants.

  • Sub-Advisor Compliance Policies and Procedures The Sub-Advisor shall promptly provide the Trust CCO with copies of: (i) the Sub-Advisor’s policies and procedures for compliance by the Sub-Advisor with the Federal Securities Laws (together, the “Sub-Advisor Compliance Procedures”), and (ii) any material changes to the Sub-Advisor Compliance Procedures. The Sub-Advisor shall cooperate fully with the Trust CCO so as to facilitate the Trust CCO’s performance of the Trust CCO’s responsibilities under Rule 38a-1 to review, evaluate and report to the Trust’s Board of Trustees on the operation of the Sub-Advisor Compliance Procedures, and shall promptly report to the Trust CCO any Material Compliance Matter arising under the Sub-Advisor Compliance Procedures involving the Sub-Advisor Assets. The Sub-Advisor shall provide to the Trust CCO: (i) quarterly reports confirming the Sub-Advisor’s compliance with the Sub-Advisor Compliance Procedures in managing the Sub-Advisor Assets, and (ii) certifications that there were no Material Compliance Matters involving the Sub-Advisor that arose under the Sub-Advisor Compliance Procedures that affected the Sub-Advisor Assets. At least annually, the Sub-Advisor shall provide a certification to the Trust CCO to the effect that the Sub-Advisor has in place and has implemented policies and procedures that are reasonably designed to ensure compliance by the Sub-Advisor with the Federal Securities Laws.

  • Development Responsibilities From and after the Effective Date, BMS shall assume sole responsibility for the Development of Compounds and Products in the Field in the Territory during the Term at its own cost and expense (including responsibility for all funding, resourcing and decision-making, subject to Sections 3.3 and 3.4), except with respect to the performance by Ambrx of the Research Program activities assigned to Ambrx pursuant to the Research Plan and as otherwise may be agreed upon by the Parties in writing. BMS, by itself or through its Affiliates and Sublicensees, shall use Diligent Efforts to Develop a Compound or Product in the Field in accordance with the Development Plan for the purpose of obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Compounds and Products may include sequential implementation of Clinical Trials and/or intervals between Clinical Trials for data interpretation and clinical program planning and approval.

Time is Money Join Law Insider Premium to draft better contracts faster.